NAD+ IV drips and supplements are often promoted as weight loss support, mainly because NAD+ does indeed play a well-documented role in metabolism. However, participating in metabolic processes is not the same as causing weight loss. Human study data on this specific issue are more mixed and require more cautious interpretation than numerous marketing messages suggest. In this article, we take a direct look at what was actually measured in studies, including body weight, BMI, fat metabolism, blood glucose regulation, and how claims regarding IV therapy stack up against the available evidence.
Does NAD+ have a direct impact on weight loss?
The most direct data come from meta-regression analysis of randomized controlled trials evaluating supplementation with NAD+ precursors, specifically nicotinic acid and nicotinamide, in relation to parameters associated with body weight.
The analysis showed that supplementation with NAD+ precursors was associated with a measurable decrease in BMI and an increase in adiponectin, a hormone involved in fat metabolism and insulin sensitivity. However, no significant effect on body mass itself or on leptin, another hormone involved in metabolic regulation, was demonstrated [1].
This distinction is important. A decrease in BMI without a statistically significant decrease in body weight suggests that the observed effect may have been small and could have depended on factors such as body composition, rather than reflecting clear and clinically significant weight loss.
The analysis also showed that the results varied depending on the specific compound. Nicotinic acid, or niacin, had a greater effect on lowering BMI than nicotinamide. The effects also appeared to be slightly stronger with higher doses and longer intervention periods [1].
Such compound-dependent differences are consistent with a broader pattern observed in NAD+ research. Individual NAD+ precursors should not be treated as fully interchangeable, and their effects may depend on the specific compound used, dosage, study population, and duration of the intervention.
For this reason, the general statement that „NAD+ helps you lose weight” is too broad to accurately reflect the available evidence. The data suggest that some NAD+-related compounds may affect selected parameters regarding body weight or metabolism, but this is not equivalent to demonstrating reproducible weight loss.
In a separate randomized, placebo-controlled trial, nicotinamide riboside was evaluated in 40 obese men with insulin resistance. Participants received 2000 mg daily for 12 weeks [2].
Researchers noted a fat-mobilization effect, meaning that NR appeared to increase the release of fatty acids into the bloodstream. This can be interpreted as an indicator of enhanced breakdown or mobilization of adipose tissue.
However, this metabolic effect did not lead to significant weight loss during the study [2].
This is a good example showing why metabolic changes should not be automatically interpreted as evidence of weight reduction. The compound can affect fat management or specific biochemical pathways without causing a measurable decrease in body weight.
How can NAD+ affect metabolism?
The broader relationship of NAD+ with metabolism is much better documented than its direct effect on weight loss.
A meta-analysis of 40 human studies involving 14,750 participants showed that NAD+ precursor supplementation, analyzed as a group, significantly reduced triglyceride, total cholesterol, and LDL cholesterol levels compared to control groups [3].
These results suggest that NAD+-related interventions may affect selected lipid parameters.
However, improving lipid parameters is not the same as losing weight. A given person may experience changes in triglycerides, cholesterol, or other metabolic biomarkers without a significant reduction in body weight.
The mechanistic link between NAD+ and metabolism also has a biological rationale.
NAD+ plays a central role in cellular energy production by participating in redox reactions related to glycolysis, the citric acid cycle, and mitochondrial ATP production. It also serves as an essential substrate for sirtuins, which are involved in the regulation of mitochondrial activity, cellular stress responses, and the expression of genes related to metabolism [4,5].
Through these pathways, changes in NAD+ availability can theoretically influence how cells utilize, store, and process nutrients.
However, mechanistic plausibility does not automatically translate into a clinically meaningful effect.
Human data clearly demonstrates this. Some studies observed changes in lipid parameters, BMI, fat mobilization, or insulin sensitivity, while a reproducible reduction in body weight was not shown in all studies.
Therefore, NAD+ should be understood as an element of metabolic biology, rather than as a directly confirmed weight-loss intervention.
Does NAD+ affect blood sugar levels?
Evidence regarding the effect of NAD+ precursors on blood glucose regulation is inconclusive and appears to depend on the studied population and the specific compound.
In one randomized, placebo-controlled, double-blind study, 250 mg of NMN per day for 10 weeks was evaluated in overweight or obese postmenopausal women with prediabetes [6].
The study showed that NMN significantly improved skeletal muscle insulin sensitivity and insulin signaling.
This is a clinically significant finding because insulin sensitivity is an important component of glucose regulation and metabolic health.
Interestingly, the improvement occurred without a detectable increase in total NAD+ content in the muscles.
Researchers also noted increased expression of a gene involved in muscle tissue remodeling, suggesting that the observed effect did not necessarily have to result solely from an increase in the total NAD+ concentration in muscles [6].
This result shows that the relationship between NAD+ precursors and glucose metabolism may involve several interacting mechanisms rather than a simple direct relationship between NAD+ levels and insulin sensitivity.
Another study yielded a less favorable result.
In a 12-week study of obese men with insulin resistance who received 2000 mg of nicotinamide riboside daily, no significant improvement in insulin sensitivity, endogenous glucose production, or overall glucose metabolism was observed [2].
This happened despite the higher dose and despite measurable metabolic effects in other areas.
The difference between these studies may be due to several factors.
One study used NMN and the other used NR. One involved postmenopausal women with prediabetes, while the other involved obese men with insulin resistance. The studies also differed in design, participant characteristics, duration, and likely baseline metabolic status.
It is therefore unknown whether the divergent results stem from differences between NMN and NR, between women and men, between the stage of metabolic disorders or other population characteristics, or from a combination of these factors.
This remains an unresolved area of research rather than an established conclusion.
A broader meta-analysis of 40 studies also evaluated fasting glucose alongside lipid outcomes, providing additional data from a much larger number of participants and various interventions [3].
Generally, in some human studies, NAD+ precursors improved insulin sensitivity or glucose-related parameters, but these results were not consistent across all compounds or populations.
For this reason, the available evidence does not support the universal claim that NAD+ lowers blood sugar.
A more precise interpretation is that some NAD+ precursors may influence glucose regulation in specific populations and conditions, while other well-designed studies have not shown a significant effect.
Is NAD+ IV therapy promoted for weight loss, and is this supported by research?
NAD+ IV therapy is commonly promoted by wellness clinics and IV therapy centers in the context of weight loss, metabolism, energy, and anti-aging.
However, the evidence supporting the intravenous route for these applications is significantly weaker than the data available for oral NAD+ precursors.
A 2026 systematic review found no eligible controlled outcome studies evaluating intravenous or intramuscular NAD+ for general wellness uses [7].
This evidentiary gap is particularly significant when evaluating weight loss claims.
Most human studies analyzing body mass, BMI, lipid metabolism, insulin sensitivity, and fat mobilization have utilized oral NAD+ precursors such as NR, NMN, nicotinic acid, or nicotinamide [1,2,3,6].
No controlled studies directly evaluating intravenous NAD+ as a weight loss intervention have been identified.
This means that marketing claims specifically linking intravenous NAD+ to weight loss are not supported by direct clinical studies of this route of administration in which weight reduction was assessed as an outcome.
These claims appear to be based primarily on the extrapolation of research concerning oral precursors and on the well-known role of NAD+ in metabolism.
Such extrapolation should be treated with caution, as different routes of administration may differ in pharmacokinetics, exposure, tolerance, dosing schedules, and biological effects.
Data from oral NR or NMN studies should therefore not be automatically applied to intravenous NAD+.
What can be expected if NAD+ is used specifically for weight loss?
If the main goal is weight loss, current human research data suggests that NAD+ precursors may influence certain metabolic and weight-related parameters, but they have not been shown to have a clear and reproducible ability to reduce body weight.
Some studies have noted a minor effect on BMI and adiponectin [1].
Other studies have shown increased fat mobilization without significant weight loss [2].
These results differ significantly from the type of evidence expected for interventions developed and tested specifically with weight reduction as the primary endpoint of a clinical trial.
The evidence is somewhat more consistent for certain metabolic biomarkers.
The large meta-analysis discussed earlier showed improvements in triglyceride, total cholesterol, and LDL cholesterol levels in studies involving various NAD+ precursors analyzed together [3].
A well-designed NMN study also demonstrated improvements in muscle insulin sensitivity in postmenopausal women with prediabetes [6].
These results may have implications for metabolic health, but should not be presented as proof that NAD+ causes weight loss.
Changes in cholesterol concentration, insulin sensitivity, adiponectin, or fat mobilization can occur without a significant decrease in body weight.
Similarly, a decrease in BMI does not necessarily mean a clinically significant loss of body fat if it is not accompanied by appropriate measurements of body weight, body composition, or fat levels.
Current evidence therefore justifies a clear distinction between metabolic effects and weight-loss effects.
NAD+ precursors can affect certain metabolic pathways and biomarkers, but they should not be expected to act like interventions specifically approved or clinically validated for weight management.
NAD+ supplementation should also not be treated as a substitute for proven methods of weight management, such as appropriate dietary changes, physical activity, behavioral interventions, treatment of underlying conditions, and evidence-based medical therapies when there are appropriate clinical indications.
Individuals considering NAD+-related products primarily for weight or metabolic goals should discuss these goals with a qualified healthcare professional, particularly in cases of obesity, prediabetes, diabetes, dyslipidemia, cardiovascular disease, or other metabolic disorders.
Limitations of current evidence
- The meta-regression result indicating a reduction in BMI without a corresponding significant decrease in body weight is complex and should be interpreted with caution. It does not prove simple or clinically significant weight loss and requires further confirmation [1].
- Part of the available data relates to nicotinic acid and nicotinamide, rather than newer NAD+ precursors such as NR or NMN. The results should not be automatically treated as applying equally to all compounds.
- The effects observed in individual studies may depend on the dose, duration of treatment, baseline metabolic state, sex, age, and the specific NAD+ precursor studied.
- Results regarding blood glucose levels and insulin sensitivity vary significantly between studies. NMN improved muscle insulin sensitivity in one study of postmenopausal women with prediabetes, whereas a separate study on NR in obese men with insulin resistance showed no significant improvement [2,6].
- The reasons for these conflicting results are not yet clear and may include differences regarding the compound, population, sex, baseline metabolic state, dose, or study design.
- A meta-analysis of 40 studies on lipid and glucose parameters combined several different NAD+ precursors, including NR, NMN, niacin, and nicotinamide. Its results therefore cannot be definitively attributed to any single specific compound [3].
- Improving triglyceride levels, cholesterol, adiponectin, insulin sensitivity, or fat mobilization does not automatically mean weight loss or fat reduction.
- BMI changes alone do not provide a full picture of body composition and should not be interpreted as direct evidence of fat loss without additional measurements.
- No controlled outcome studies evaluating intravenous NAD+ specifically in the context of weight reduction or metabolic effects have been identified [7].
- Claims that intravenous NAD+ supports weight loss are therefore based primarily on mechanistic reasoning or extrapolation from studies of oral precursors, rather than on direct evidence regarding IV therapy.
- Research results for oral NR, NMN, niacin, or nicotinamide should not be automatically generalized to intravenous, intramuscular, or other routes of NAD+ administration.
- Most studies have had a relatively short duration, so the long-term impact of NAD+ precursor supplementation on body weight, body composition, glucose regulation, and metabolic health remains less certain.
Disclaimer
The article is for educational purposes only and summarizes scientific research. It does not constitute medical advice, weight management guidelines, or therapeutic recommendations.
NAD+ and its precursors should not be presented as FDA- or EMA-approved treatments for obesity, weight loss, diabetes, insulin resistance, dyslipidemia, or other metabolic diseases, unless referring to a specific approved medicinal product and indication.
Changes in NAD+ levels, lipid parameters, insulin sensitivity, adiponectin, fat mobilization, or other metabolic biomarkers should not be interpreted as evidence of clinically significant weight loss.
Individuals seeking weight loss or the treatment of metabolic disorders should use evidence-based methods appropriate to their individual health status, rather than relying solely on NAD+ supplementation.
Before starting any new supplement or therapy to reduce body weight or improve metabolism, you should consult a qualified healthcare professional, especially during pregnancy or breastfeeding, in cases of diabetes, prediabetes, obesity, cardiovascular disease, liver disease, kidney disease, or other chronic conditions, as well as when taking prescription medications.
References
[1] You, B., Gomes Reis, M., Tavakoli, S., Khodadadi, N., Sohouli, M. H., & Sernizon Guimarães, N. (2023). The effects of NAD+ precursor (nicotinic acid and nicotinamide) supplementation on weight loss and related hormones: A systematic review and meta-regression analysis of randomized controlled trials. Frontiers in Nutrition, 10, 1208734. https://doi.org/10.3389/fnut.2023.1208734
[2] Dollerup, O. L., Christensen, B., Svart, M., Schmidt, M. S., Sulek, K., Ringgaard, S., Stødkilde-Jørgensen, H., Møller, N., Brenner, C., Treebak, J. T., & Jessen, N. (2018). A randomized placebo-controlled clinical trial of nicotinamide riboside in obese men: Safety, insulin-sensitivity, and lipid-mobilizing effects. American Journal of Clinical Nutrition, 108(2), 343–353. https://doi.org/10.1093/ajcn/nqy132
[3] Zhong, O., Wang, J., Tan, Y., Lei, X., & Tang, Z. (2022). Effects of NAD+ precursor supplementation on glucose and lipid metabolism in humans: A meta-analysis. Nutrition & Metabolism, 19, 20. https://doi.org/10.1186/s12986-022-00653-9
[4] Yoshino, J., Baur, J. A., & Imai, S. (2018). NAD+ intermediates: The biology and therapeutic potential of NMN and NR. Cell Metabolism, 27(3), 513–528. https://doi.org/10.1016/j.cmet.2017.11.002
[5] Covarrubias, A. J., Perrone, R., Grozio, A., & Verdin, E. (2021). NAD+ metabolism and its roles in cellular processes during ageing. Nature Reviews Molecular Cell Biology, 22(2), 119–141. https://doi.org/10.1038/s41580-020-00313-x
[6] Yoshino, M., Yoshino, J., Kayser, B. D., Patti, G. J., Franczyk, M. P., Mills, K. F., Sindelar, M., Pietka, T., Patterson, B. W., Imai, S.-I., & Klein, S. (2021). Nicotinamide mononucleotide increases muscle insulin sensitivity in prediabetic women. Science, 372(6547), 1224–1229. https://doi.org/10.1126/science.abe9985
[7] Gallagher, C., & Emmanuel, O. O. (2026). NAD+ supplementation for anti-aging and wellness: A PRISMA-guided systematic review of preclinical and clinical evidence. Ageing Research Reviews, 116, 103057. https://doi.org/10.1016/j.arr.2026.103057